Founded in 2008 by industry veterans Richard Wagner, Brant Binder, and Gordon Binder, X-BODY is a privately held biotechnology company with a mission to apply its innovative capabilities and diverse DNA-tagged human antibody library to discover human antibodies against novel therapeutic targets in the fields of oncology and ophthalmology. Through strategic alliances with other corporations, X-BODY generates antibody therapeutic candidates, while also focusing on its internal efforts to develop compounds against biologically relevant targets. The company's technologies enable the production of stable and functional binding molecules, making it a leading developer of human monoclonal antibody therapeutics in the biotech industry.